Itziar Canamasas, Global Head of Oncology at Boehringer Ingelheim, shared Boehringer Ingelheim’s post on LinkedIn, adding:
“Precision oncology is not just about finding the right treatment. It is about making that treatment available at the right moment.
The earlier we can act on our understanding of the biology driving a cancer, the greater the opportunity to change the course of care.
That is why I am particularly excited to see our targeted therapy approved in Japan for the first-line treatment of HER2 (ERBB2)-mutant NSCLC. This is an important milestone in bringing biomarker-driven treatment approaches to people from the very beginning of their treatment journey.
At Boehringer Ingelheim, we are driven by the ambition to make precision medicine a reality for more people, earlier. Progress like this brings us another step closer to that vision.”
Quoting Boehringer Ingelheim:
“Our targeted therapy is now approved in Japan as a first-line treatment option for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer death in Japan. For eligible patients, this approval means targeted therapy can begin right from the start of their treatment journey, rather than only after previous treatment. An important step forward for people facing HER2-driven lung cancer.
About Itziar Canamasas
Itziar Canamasas is a pharmaceutical industry leader who serves as Global Head of Oncology at Boehringer Ingelheim. She has a PhD in Cancer Genetics from Johannes Gutenberg University Mainz and over 20 years of experience in the biopharmaceutical sector, particularly in oncology, precision medicine and drug development.
At Boehringer Ingelheim, she leads the company’s oncology efforts, with a focus on developing targeted cancer treatments and making advances in precision medicine more accessible to patients.
About Boehringer Ingelheim
Founded in 1885, Boehringer Ingelheim is a family-owned pharmaceutical company based in Ingelheim, Germany. It operates in more than 130 markets worldwide, developing medicines for people and animals.
The company’s research spans several areas of medicine, including cancer, cardiovascular and metabolic diseases, respiratory conditions and immunology. In oncology, Boehringer Ingelheim works on new treatment options, with a particular focus on precision medicine and cancers where existing therapies still leave significant unmet needs.
You may also be interested in:
- Itziar Canamasas: Why Tumor Biology Matters in Precision Oncology
- Boehringer Ingelheim Expands Its Cancer Innovation Pipeline With SBP Group